Anika Therapeutics
ANIK
122 hedge funds and large institutions have $324M invested in Anika Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 49 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
7% more funds holding
Funds holding: 114 → 122 (+8)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more call options, than puts
Call options by funds: $5K | Put options by funds: $5K
0.62% less ownership
Funds ownership: 89.09% → 88.47% (-0.62%)
4% less capital invested
Capital invested by funds: $335M → $324M (-$11.8M)
29% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.09M |
| 2 |
RP
Riverwater Partners
Milwaukee,
Wisconsin
|
+$2.23M |
| 3 |
MIM
Meros Investment Management
Dallas,
Texas
|
+$637K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$620K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$465K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.99M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$1.52M |
| 3 |
Morgan Stanley
New York
|
-$1.27M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.22M |
| 5 |
VIA
Virtus Investment Advisers
Hartford,
Connecticut
|
-$1.15M |
ANIK Hedge Fund Activity: Q3 2024 in Review
122 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2024, worth a combined $324M — down 3.5% from $335M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ANIK positions and 6 closed out — a net gain of 8 holders — while 35 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock, adding an estimated $4.09M. The largest seller was AQR Capital Management, cutting an estimated $1.99M.
- 122 institutional investors held Anika Therapeutics (ANIK) as of Q3 2024, up from 114 in Q2 2024.
- Funds reported $324M of Anika Therapeutics stock for Q3 2024, down 3.5% quarter-over-quarter.
- 14 funds opened new Anika Therapeutics positions in Q3 2024 and 6 closed out, a net change of +8 holders.
- The largest Anika Therapeutics buyer in Q3 2024 was BlackRock, an estimated $4.09M added.
- The largest Anika Therapeutics seller in Q3 2024 was AQR Capital Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2024.